Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics

Bibliography

• Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006;6(4):321-30
   PubMed Web of Science ®Google Scholar
• Llamazares S, Moreira A, Tavares A, Polo encodes a protein kinase homolog required for mitosis in Drosophila. Genes Dev 1991;5(12A):2153-65
   PubMed Web of Science ®Google Scholar
• Barr FA, Sillje HH, Nigg EA. Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 2004;5(6):429-40
   PubMed Web of Science ®Google Scholar
• Golsteyn RM, Schultz SJ, Bartek J, Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5. J Cell Sci 1994;107(Pt 6):1509-17
   PubMedGoogle Scholar
• Liby K, Wu H, Ouyang B, Identification of the human homologue of the early-growth response gene Snk, encoding a serum-inducible kinase. DNA Seq 2001;11(6):527-33
   PubMedGoogle Scholar
• Ma S, Liu MA, Yuan YL, Erikson RL. The serum-inducible protein kinase Snk is a G1 phase polo-like kinase that is inhibited by the calcium- and integrin-binding protein CIB. Mol Cancer Res 2003;1(5):376-84
   PubMed Web of Science ®Google Scholar
• Bahassi el M, Conn CW, Myer DL, Mammalian Polo-like kinase 3 (Plk3) is a multifunctional protein involved in stress response pathways. Oncogene 2002;21(43):6633-40
   PubMed Web of Science ®Google Scholar
• Xie S, Wu H, Wang Q, Genotoxic stress-induced activation of Plk3 is partly mediated by Chk2. Cell Cycle 2002;1(6):424-9
   PubMedGoogle Scholar
• Burns TF, Fei P, Scata KA, Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol 2003;23(16):5556-71
   PubMed Web of Science ®Google Scholar
• Ruan Q, Wang Q, Xie S, Polo-like kinase 3 is Golgi localized and involved in regulating Golgi fragmentation during the cell cycle. Exp Cell Res 2004;294(1):51-9
   PubMed Web of Science ®Google Scholar
• Xie S, Wang Q, Ruan Q, MEK1-induced Golgi dynamics during cell cycle progression is partly mediated by Polo-like kinase-3. Oncogene 2004;23(21):3822-9
   PubMed Web of Science ®Google Scholar
• Pak DT, Sheng M. Targeted protein degradation and synapse remodeling by an inducible protein kinase. Science 2003;302(5649):1368-73
   PubMed Web of Science ®Google Scholar
• Leung GC, Hudson JW, Kozarova A, The Sak polo-box comprises a structural domain sufficient for mitotic subcellular localization. Nat Struct Biol 2002;9(10):719-24
   PubMedGoogle Scholar
• Hudson JW, Kozarova A, Cheung P, Late mitotic failure in mice lacking Sak, a polo-like kinase. Curr Biol 2001;11(6):441-6
   PubMed Web of Science ®Google Scholar
• Cheng KY, Lowe ED, Sinclair J, The crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex. EMBO J 2003;22(21):5757-68
   PubMed Web of Science ®Google Scholar
• Kothe M, Kohls D, Low S, Structure of the catalytic domain of human polo-like kinase 1. Biochemistry 2007;46(20):5960-71
   PubMed Web of Science ®Google Scholar
• Elia AE, Rellos P, Haire LF, The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. Cell 2003;115(1):83-95
   PubMed Web of Science ®Google Scholar
• Jang YJ, Lin CY, Ma S, Erikson RL. Functional studies on the role of the C-terminal domain of mammalian polo-like kinase. Proc Natl Acad Sci USA 2002;99(4):1984-9
   PubMed Web of Science ®Google Scholar
• Ito Y, Miyoshi E, Sasaki N, Polo-like kinase 1 overexpression is an early event in the progression of papillary carcinoma. Br J Cancer 2004;90(2):414-8
   PubMed Web of Science ®Google Scholar
• Dai W, Wang Q, Traganos F. Polo-like kinases and centrosome regulation. Oncogene 2002;21(40):6195-200
   PubMed Web of Science ®Google Scholar
• Golsteyn RM, Mundt KE, Fry AM, Nigg EA. Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function. J Cell Biol 1995;129(6):1617-28
   PubMed Web of Science ®Google Scholar
• Alvarez B, Martinez AC, Burgering BM, Carrera AC. Forkhead transcription factors contribute to execution of the mitotic programme in mammals. Nature 2001;413(6857):744-7
   PubMed Web of Science ®Google Scholar
• Anger M, Kues WA, Klima J, Cell cycle dependent expression of Plk1 in synchronized porcine fetal fibroblasts. Mol Reprod Dev 2003;65(3):245-53
   PubMed Web of Science ®Google Scholar
• Lake RJ, Jelinek WR. Cell cycle- and terminal differentiation-associated regulation of the mouse mRNA encoding a conserved mitotic protein kinase. Mol Cell Biol 1993;13(12):7793-801
   PubMed Web of Science ®Google Scholar
• Lee KS, Yuan YL, Kuriyama R, Erikson RL. Plk is an M-phase-specific protein kinase and interacts with a kinesin-like protein, CHO1/MKLP-1. Mol Cell Biol 1995;15(12):7143-51
   PubMed Web of Science ®Google Scholar
• Hamanaka R, Maloid S, Smith MR, Cloning and characterization of human and murine homologues of the Drosophila polo serine-threonine kinase. Cell Growth Differ 1994;5(3):249-57
   PubMedGoogle Scholar
• Holtrich U, Wolf G, Brauninger A, Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci USA 1994;91(5):1736-40
   PubMed Web of Science ®Google Scholar
• Wolf G, Hildenbrand R, Schwar C, Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer. Pathol Res Pract 2000;196(11):753-9
   PubMed Web of Science ®Google Scholar
• Syed V, Hecht NB. Rat pachytene spermatocytes down-regulate a polo-like kinase and up-regulate a thiol-specific antioxidant protein, whereas sertoli cells down-regulate a phosphodiesterase and up-regulate an oxidative stress protein after exposure to methoxyethanol and methoxyacetic acid. Endocrinology 1998;139(8):3503-11
   PubMed Web of Science ®Google Scholar
• Georgescu SP, Komuro I, Hiroi Y, Downregulation of polo-like kinase correlates with loss of proliferative ability of cardiac myocytes. J Mol Cell Cardiol 1997;29(3):929-37
   PubMed Web of Science ®Google Scholar
• Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I. Polo-like kinases (Plks) and cancer. Oncogene 2005;24(2):287-91
   PubMed Web of Science ®Google Scholar
• Yuan J, Horlin A, Hock B, Polo-like kinase, a novel marker for cellular proliferation. Am J Pathol 1997;150(4):1165-72
   PubMed Web of Science ®Google Scholar
• Eckerdt F, Yuan J, Strebhardt K. Polo-like kinases and oncogenesis. Oncogene 2005;24(2):267-76
   PubMed Web of Science ®Google Scholar
• Simmons DL, Neel BG, Stevens R, Identification of an early-growth-response gene encoding a novel putative protein kinase. Mol Cell Biol 1992;12(9):4164-9
   PubMed Web of Science ®Google Scholar
• Seki A, Coppinger JA, Jang CY, Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry. Science 2008;320(5883):1655-8
   PubMed Web of Science ®Google Scholar
• Macurek L, Lindqvist A, Lim D, Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature 2008;455(7209):119-23
   PubMed Web of Science ®Google Scholar
• Kumagai A, Dunphy WG. Purification and molecular cloning of Plx1, a Cdc25-regulatory kinase from Xenopus egg extracts. Science 1996;273(5280):1377-80
   PubMed Web of Science ®Google Scholar
• Toyoshima-Morimoto F, Taniguchi E, Nishida E. Plk1 promotes nuclear translocation of human Cdc25C during prophase. EMBO Rep 2002;3(4):341-8
   PubMed Web of Science ®Google Scholar
• Toyoshima-Morimoto F, Taniguchi E, Shinya N, Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase. Nature 2001;410(6825):215-20
   PubMed Web of Science ®Google Scholar
• Yuan J, Eckerdt F, Bereiter-Hahn J, Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1. Oncogene 2002;21(54):8282-92
   PubMed Web of Science ®Google Scholar
• Walsh S, Margolis SS, Kornbluth S. Phosphorylation of the cyclin b1 cytoplasmic retention sequence by mitogen-activated protein kinase and Plx. Mol Cancer Res 2003;1(4):280-9
   PubMed Web of Science ®Google Scholar
• Lee KS, Erikson RL. Plk is a functional homolog of Saccharomyces cerevisiae Cdc5, and elevated Plk activity induces multiple septation structures. Mol Cell Biol 1997;17(6):3408-17
   PubMed Web of Science ®Google Scholar
• van Vugt MA, van de Weerdt BC, Vader G, Polo-like kinase-1 is required for bipolar spindle formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis. J Biol Chem 2004;279(35):36841-54
   PubMed Web of Science ®Google Scholar
• Sunkel CE, Glover DM. Polo, a mitotic mutant of Drosophila displaying abnormal spindle poles. J Cell Sci 1988;89(Pt 1):25-38
   PubMedGoogle Scholar
• Ohkura H, Hagan IM, Glover DM. The conserved Schizosaccharomyces pombe kinase plo1, required to form a bipolar spindle, the actin ring, and septum, can drive septum formation in G1 and G2 cells. Genes Dev 1995;9(9):1059-73
   PubMed Web of Science ®Google Scholar
• Gonzalez C, Sunkel CE, Glover DM. Interactions between mgr, asp, and polo: asp function modulated by polo and needed to maintain the poles of monopolar and bipolar spindles. Chromosoma 1998;107(6-7):452-60
   PubMed Web of Science ®Google Scholar
• Donaldson MM, Tavares AA, Ohkura H, Metaphase arrest with centromere separation in polo mutants of Drosophila. J Cell Biol 2001;153(4):663-76
   PubMed Web of Science ®Google Scholar
• Kang D, Chen J, Wong J, Fang G. The checkpoint protein Chfr is a ligase that ubiquitinates Plk1 and inhibits Cdc2 at the G2 to M transition. J Cell Biol 2002;156(2):249-59
   PubMed Web of Science ®Google Scholar
• Moshe Y, Boulaire J, Pagano M, Hershko A. Role of Polo-like kinase in the degradation of early mitotic inhibitor 1, a regulator of the anaphase promoting complex/cyclosome. Proc Natl Acad Sci USA 2004;101(21):7937-42
   PubMed Web of Science ®Google Scholar
• Hansen DV, Loktev AV, Ban KH, Jackson PK. Plk1 regulates activation of the anaphase promoting complex by phosphorylating and triggering SCFbetaTrCP-dependent destruction of the APC Inhibitor Emi1. Mol Biol Cell 2004;15(12):5623-34
   PubMed Web of Science ®Google Scholar
• Ahonen LJ, Kallio MJ, Daum JR, Polo-like kinase 1 creates the tension-sensing 3F3/2 phosphoepitope and modulates the association of spindle-checkpoint proteins at kinetochores. Curr Biol 2005;15(12):1078-89
   PubMed Web of Science ®Google Scholar
• Wolf G, Elez R, Doermer A, Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 1997;14(5):543-9
   PubMed Web of Science ®Google Scholar
• Knecht R, Elez R, Oechler M, Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res 1999;59(12):2794-7
   PubMed Web of Science ®Google Scholar
• Tokumitsu Y, Mori M, Tanaka S, Prognostic significance of polo-like kinase expression in esophageal carcinoma. Int J Oncol 1999;15(4):687-92
   PubMed Web of Science ®Google Scholar
• Dietzmann K, Kirches E, von B, Increased human polo-like kinase-1 expression in gliomas. J Neurooncol 2001;53(1):1-11
   PubMed Web of Science ®Google Scholar
• Takahashi T, Sano B, Nagata T, Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 2003;94(2):148-52
   PubMed Web of Science ®Google Scholar
• Takai N, Miyazaki T, Fujisawa K, Polo-like kinase (PLK) expression in endometrial carcinoma. Cancer Lett 2001;169(1):41-9
   PubMed Web of Science ®Google Scholar
• Kneisel L, Strebhardt K, Bernd A, Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol 2002;29(6):354-8
   PubMed Web of Science ®Google Scholar
• Weichert W, Denkert C, Schmidt M, Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer 2004;90(4):815-21
   PubMed Web of Science ®Google Scholar
• Lane HA, Nigg EA. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 1996;135(6 Pt 2):1701-13
   PubMed Web of Science ®Google Scholar
• Liu X, Erikson RL. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003;100(10):5789-94
   PubMed Web of Science ®Google Scholar
• Reagan-Shaw S, Ahmad N. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer. FASEB J 2005;19(6):611-3
   PubMedGoogle Scholar
• Guan R, Tapang P, Leverson JD, Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 2005;65(7):2698-704
   PubMed Web of Science ®Google Scholar
• Spankuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, Strebhardt K. Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 2002;94(24):1863-77
   PubMed Web of Science ®Google Scholar
• Spankuch B, Matthess Y, Knecht R, Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst 2004;96(11):862-72
   PubMed Web of Science ®Google Scholar
• Smith MR, Wilson ML, Hamanaka R, Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun 1997;234(2):397-405
   PubMed Web of Science ®Google Scholar
• Zhou Q, Su Y, Bai M. Effect of antisense RNA targeting Polo-like kinase 1 on cell growth in A549 lung cancer cells. J Huazhong Univ Sci Technolog Med Sci 2008;28(1):22-6
   PubMed Web of Science ®Google Scholar
• Lansing TJ, McConnell RT, Duckett DR, In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. Mol Cancer Ther 2007;6(2):450-9
   PubMed Web of Science ®Google Scholar
• Spankuch B, Heim S, Kurunci-Csacsko E, Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo. Cancer Res 2006;66(11):5836-46
   PubMed Web of Science ®Google Scholar
• Lee M, Daniels MJ, Venkitaraman AR. Phosphorylation of BRCA2 by the Polo-like kinase Plk1 is regulated by DNA damage and mitotic progression. Oncogene 2004;23(4):865-72
   PubMed Web of Science ®Google Scholar
• Takai N, Miyazaki T, Fujisawa K, Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage. Cancer Lett 2001;164(1):41-9
   PubMed Web of Science ®Google Scholar
• Macmillan JC, Hudson JW, Bull S, Comparative expression of the mitotic regulators SAK and PLK in colorectal cancer. Ann Surg Oncol 2001;8(9):729-40
   PubMed Web of Science ®Google Scholar
• Ito Y, Yoshida H, Matsuzuka F, Polo-like kinase 1 (PLK1) expression is associated with cell proliferative activity and cdc2 expression in malignant lymphoma of the thyroid. Anticancer Res 2004;24(1):259-63
   PubMed Web of Science ®Google Scholar
• Petronczki M, Lenart P, Peters JM. Polo on the rise-from mitotic entry to cytokinesis with Plk1. Dev Cell 2008;14(5):646-59
   PubMed Web of Science ®Google Scholar
• Schoffski P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 2009;14(6):559-70
   PubMed Web of Science ®Google Scholar
• McInnes C, Mazumdar A, Mezna M, Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance. Nat Chem Biol 2006;2(11):608-17
   PubMed Web of Science ®Google Scholar
• Peters U, Cherian J, Kim JH, Probing cell-division phenotype space and Polo-like kinase function using small molecules. Nat Chem Biol 2006;2(11):618-26
   PubMed Web of Science ®Google Scholar
• Lenart P, Petronczki M, Steegmaier M, The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 2007;17(4):304-15
   PubMed Web of Science ®Google Scholar
• Steegmaier M, Hoffmann M, Baum A, BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007;17(4):316-22
   PubMed Web of Science ®Google Scholar
• Von Pawel J, Reck M, Digel W, Randomized phase II trial of two dosing schedules of BI 2536, a novel Plk-1 inhibitor, in patients with relapsed advanced or metastatic non-small-cell lung cancer (NSCLC). J Clin Oncol 26;2008 (May 20 suppl; abstr 8030)
   Google Scholar
• Pandha HS, Protheroe A, Wylie J, An open label phase II trial of BI 2536, a novel Plk1 inhibitor, in patients with metastatic hormone refractory prostate cancer (HRPC) [abstract]. J Clin Oncol 2008;26:14547
   Google Scholar
• Rudolph D, Steegmaier M, Hoffmann M, Characterization of BI 6727, a novel Polo-like kinase inhibitor with a distinct pharmacokinetic profile and efficacy in a model of taxane-resistant colon cancer. Presented at the 20th European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland, October 21–24, 2008 Abstract number 430
   Google Scholar
• Sumara I, Gimenez-Abian JF, Gerlich D, Roles of polo-like kinase 1 in the assembly of functional mitotic spindles. Curr Biol 2004;14(19):1712-22
   PubMed Web of Science ®Google Scholar
• Schöffski P, Awada A, Dumez H, A Phase I single dose escalation study of the novel Polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumors. Eur J Cancer Suppl 2008;6:14-5
   Google Scholar
• Rudolph D, Steegmaier M, Hoffmann M, BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 2009;15(9):3094-102
   PubMed Web of Science ®Google Scholar
• Laquerre S, Shung C-M, Gilmartin A, A potent and selective Polo-like kinase 1 (Plk1) inhibitor (GSK461364) induces cell cycle arrest and growth inhibition of cancer cell. Presented at the 98th American Association for Cancer Research Annual Meeting, Los Angeles, CA, April 14–18, 2007 . Abstract number 5389
   Google Scholar
• Gilmartin AG, Bleam MR, Richter MC, Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. Cancer Res 2009;69(17):6969-77
   PubMed Web of Science ®Google Scholar
• Sutton D, Diamond M, Faucette L, GSK923295A, a potent and selective CENP-E inhibitor, has broad spectrum activity against human tumor xenografts in nude mice [abstract #1522]. Proc Am Ass Cancer Res 2007 [Meeting Report]
   Google Scholar
• Palmieri D, Hau E, Qian Y, Preclinical studies investigating the efficacy of GSK461364A, an inhibitor of Polo-like kinase-1, for the prevention of breast cancer brain metastases. Presented at the American Association for Cancer Research 2009 Annual Meeting, Denver, CO, April 18-22, 2009 . Abstract number 4767
   Google Scholar
• Gumireddy K, Reddy MV, Cosenza SC, ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 2005;7(3):275-86
   PubMed Web of Science ®Google Scholar
• Chapman CM, Patricia PG, Wiestner A. ON 01910.Na, a novel clinical grade PLK-1 inhibitor, selectively induces apoptosis in human B-cell chronic lymphocytic leukemia (B-CLL). Presented at the American Association of Cancer Research 2009 Annual Meeting, Denver, CO, April 18–22, 2009 . Abstract number 3654
   Google Scholar
• ILEX Oncology IH-isb. HMN-214 investigator's brochure; 2000
   Google Scholar
• Garland LL, Taylor C, Pilkington DL, A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors. Clin Cancer Res 2006;12(17):5182-9
   PubMed Web of Science ®Google Scholar
• Takagi M, Honmura T, Watanabe S, In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176. Invest New Drugs 2003;21(4):387-99
   PubMed Web of Science ®Google Scholar
• Reindl W, Yuan J, Kramer A, Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem Biol 2008;15(5):459-66
   PubMed Web of Science ®Google Scholar
• Watanabe N, Sekine T, Takagi M, Deficiency in chromosome congression by the inhibition of Plk1 polo box domain-dependent recognition. J Biol Chem 2009;284(4):2344-53
   PubMed Web of Science ®Google Scholar
• Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006;2(7):358-64
   PubMed Web of Science ®Google Scholar
• Keppner S, Proschak E, Schneider G, Spankuch B. Identification and validation of a potent type II inhibitor of inactive Polo-like kinase 1. ChemMedChem 2009;4(11):18609-9
   Google Scholar
• Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4(4):253-65
   PubMed Web of Science ®Google Scholar
• McInnes C, Mezna M, Fischer PM. Progress in the discovery of polo-like kinase inhibitors. Curr Top Med Chem 2005;5(2):181-97
   PubMed Web of Science ®Google Scholar
• Yang Y, Bai J, Shen R, Polo-like kinase 3 functions as a tumor suppressor and is a negative regulator of hypoxia-inducible factor-1 alpha under hypoxic conditions. Cancer Res 2008;68(11):4077-85
   PubMed Web of Science ®Google Scholar